Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT01273337
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Aldagen
- Registry
-
NCT01273337
-
- Other papers using this trial's data
- A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke)
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT01273337. Randomized; quadruple masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2014-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
- Condition
- Stroke
- Condition
- Ischemic Stroke
- Condition
- Stroke in Middle Cerebral Artery (MCA)
- Intervention (Biological)
- ALD-401
- Intervention (Procedure)
- Sham Procedure
- Lead sponsor
- Aldagen
Record details
- Record id
cardio:ct-nct01273337- Content hash
df6274daa35178bdbe17a6f85d597f25c1b3ed08b27682ebe8cecf6d035c1cdb